Molecular phenotypes of critical illness confer prognostic and biological enrichment in sub-Saharan Africa: a prospective cohort study from Uganda

The generalisability of critical illness molecular phenotypes to low- and middle-income countries (LMICs) is unknown. We show that molecular phenotypes derived in high-income countries (hyperinflammatory and hypoinflammatory, reactive and uninflamed) stratify sepsis patients in Uganda by physiologic...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorax Ročník 80; číslo 3; s. 175 - 179
Hlavní autoři: Cummings, Matthew J, Lutwama, Julius J, Tomoiaga, Alin S, Owor, Nicholas, Lu, Xuan, Ross, Jesse E, Muwanga, Moses, Nsereko, Christopher, Nayiga, Irene, Nie, Kai, Kayiwa, John, Che, Xiaoyu, Wayengera, Misaki, Kim-Schulze, Seunghee, Lipkin, W Ian, O’Donnell, Max R, Bakamutumaho, Barnabas
Médium: Journal Article
Jazyk:angličtina
Vydáno: England BMJ Publishing Group Ltd and British Thoracic Society 17.02.2025
BMJ Publishing Group LTD
Témata:
ISSN:0040-6376, 1468-3296, 1468-3296
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The generalisability of critical illness molecular phenotypes to low- and middle-income countries (LMICs) is unknown. We show that molecular phenotypes derived in high-income countries (hyperinflammatory and hypoinflammatory, reactive and uninflamed) stratify sepsis patients in Uganda by physiological severity, mortality risk and dysregulation of key pathobiological domains. A classifier model including data available at the LMIC bedside modestly discriminated phenotype assignment (area under the receiver operating characteristic curve (AUROC) 0.80, 95% CI 0.71 to 0.90 for hyperinflammatory vs hypoinflammatory; AUROC 0.74, 95% CI 0.65 to 0.83 for reactive vs uninflamed). Our findings highlight the potential for a globally relevant, clinicomolecular classification of critical illness and may support the inclusion of diverse populations in phenotype-targeted critical care trials. Improved laboratory capacity and access to rapid biomarker assays are likely necessary to optimise phenotype stratification in LMIC settings.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0040-6376
1468-3296
1468-3296
DOI:10.1136/thorax-2024-222412